Please login to the form below
UCB’s Mark Bodmer elected to BIA board
Will hold the position for a three-year fixed term
UCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).
Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.
As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.
Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.
His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.
Featured jobs
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
-
Account Director, Medical Education
-
Salary TBC
-
Senior External Communications Lead
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director
-
£Competitive Salary
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Publications director
-
Competitive salary and bonus scheme
-
Account Manager
-
£Competitive Salary
- Client Services Director - Digital MedComms
-
£60000 - £80000 per annum, Benefits: Pension, healthcare, dedicated training budget, regul
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
-
Account director
-
Competitive salary and bonus scheme
Subscribe to our email news alerts
- Novartis faces criticism over Zolgensma ‘health lottery’
- Novartis plans inclisiran trial in the UK
- Merck chases Roche with triple-negative breast cancer data for Keytruda
- AZ revenues rise, but it says coronavirus could hit 2020
- Novartis pulls ahead of Merck in MET-positive lung cancer race
- Novartis plans inclisiran trial in the UK
- AZ revenues rise, but it says coronavirus could hit 2020
- Seattle Genetics wins FDA priority review for oral HER2 drug
- Eisai agrees to pull obesity drug Belviq after safety alert
- FDA begins speedy review of BMS’ CAR-T liso-cel
- It’s Teenage Kicks for Lucid Group
- 20 for 2020 – Five pharma companies to watch
No results were found
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- 20 for 2020 – Five pharma companies to watch
- As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
- The growing clinical importance of patient-reported outcomes (PROs)
- Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
- The roaring ‘20s and Generation Z
- How a new generation will shape pharma comms this decade...
Quick links
Infographics
